Cash & equivalents increased 116.0%
Cash & equivalents changed +116.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Cash & equivalents changed +116.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current assets changed +106.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current liabilities changed +103.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Total assets changed +80.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating cash flow changed +27.0% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Research & development changed +61.6% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Operating income changed -18.3% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.